Pharma-News
33 views | +0 today
Follow
Pharma-News
Industry News
Your new post is loading...
Your new post is loading...
Scooped by mark igbinedion
Scoop.it!

Reckitt Benckiser eyes pharmaceutical unit spin-off - Financial Times

Reckitt Benckiser eyes pharmaceutical unit spin-off - Financial Times | Pharma-News | Scoop.it
Economic Times
Reckitt Benckiser eyes pharmaceutical unit spin-off
Financial Times
Reckitt Benckiser says it is leaning towards a spin-off of the pharmaceuticals division it put under strategic review in October.
more...
No comment yet.
Rescooped by mark igbinedion from Industry Research Reports
Scoop.it!

Mature Biotech: Biotechnology & Pharmaceutical Industry Outlook 2014

Check for Discount on Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech report by MP Advisors. Positive sentiments for the biotech sector have prevailed in...

Via isha3994
more...
isha3994's curator insight, January 21, 2014 3:24 AM

Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech


Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com  with (Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech) / report name in subject line and your contact details.       

    

Positive sentiments for the biotech sector have prevailed in the last two to three years, and the reseacrh expect this trend to continue for the next year too.  The report optimism is based on the continuity in the flow of innovative products from their pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats – which all lend stability to the business model of the company.  Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space.

 

Complete report of 72 Pages is available @ http://www.reportsnreports.com/reports/273310-global-pharmaceutical-biotechnology-outlook-2014-mature-biotech.html.


In the next five years the distinction between some mature biotech companies and large global pharma may become blurred esp. if there is consolidation within the sector.  AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira’s infliximab – Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway is defined in US.

The detailed 72 pages report contains the detailed discussion of the key attributes of leading biotech companies’ Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex.

 

Table Of Contents

Macro Analysis
Key Attributes of Leading Biotech Companies
New Drug Approval in 2013-16
Key Milestones during 2014/15
Merger and Acquisitions
Biosimilars in developments

Inquiry Before Buying on this Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=273310

 

In-depth Company Analysis and Reports on

1.Acorda Therapeutics – Pipeline of NDDS Drugs tar geting Niche Indications

Marketed Products - Ampyra and Qutenza
Label expansion of Ampyra
Pipeline beyond Ampyra

 

2. Alexion Pharma – Focus on Innovative Drugs for Orphan/Ultra-rare Diseases With No Competition Visible!


Product Pipeline – Future Potential
Soliris in PNH and aHUS: Growth to Continue
Soliris beyond PNH and aHUS
Diversifying Beyond Soliris - Asfotase alfa
Early stage programs – Cyclic Pyranopterin Monophosphate,ALXN1007,ALXN1 102

 

3. Amgen – Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds
Late-Stage Pipeline
Biosimilar Opportunity & Competition
Partnership and Acquisitions
Competitive Landscape: Anti-PCSK9 mAb – Hyperlipidemia

 

4. Biogen Idec – Near Term Growth Prospects Driven by Core Business + New Product Launches
TECFIDERA
Long-Acting Hemophilia Drugs – ELOCTATE and ALPROLIX
Detailed data from long-lasting recombinant FVIII and FIX
Superiority of Gazyva against Rituxan in CLL
BIIB’s MS Franchise – Strengthening its Leadership
MULTIPLE SCLEROSIS – INJECTABLE DRUGS DATA COMPARISON
MULTIPLE SCLEROSIS – ORAL DRUGS DATA COMPARISON

 

5. Celgene – Innovative Strategies for Long Term Gains
Growth from marketed products and label expansion of Revlimid,ABRAXANE,
POMALYST/IMNOVID,Vidaza
Novel Early Stage Products - Sotatercept,ACE-536, CC-292, MOR202, CC-223,EPZ5676, CC-220
Collaborations

 

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=273310.


6. Gilead Sciences – Poised to Emerge as a Leader in HCV Treatment
Sofosbuvir/ Ledispavir FDC
Development Pipeline
HIV Life cycle management
Beyond Anti-Virals – Idelalisib, Momelotinib, Simtuzumab, GS-9973
Acquisitions
Technology platform – Dual-Afnity Re-Targeting (DART)

 

7. Regeneron – Label Expansion Sustains Eylea’s Growth Momentum + Late Stage Pipeline
Potential Poised For Further Contribution
Marketed Products – Eylea, Arcalyst, ZALTRAP
Label expansion of Eylea in DME and BRVO indication
Late-Stage Pipeline - Alirocumab, Sarilumab, Dupilumab
REGN-Sano Collaboration
BRANCH RETINAL VEIN OCCLUSION (BRVO): CLINICAL DATA ANALYSIS
COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB – HYPERLIPIDEMIA

 

Buy a copy of report http://www.reportsnreports.com/purchase.aspx?name=273310.


8. Vertex Pharma – Focus Shift to Cystic Fibrosis and Niche Indications
Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation
Small But Meaningful Addition in Other Mutations for KALYDECO
PhII data from KALYDECO / VX-809
PHIII studies for KALYDECO and VX- 809/KALYDECO in homozygous CF pts
HCV Glory Faded Very Soon
Beyond CF and HCV – VX-509, VX-787, VX-767
KEY Pipeline Products: IFN-Free Combinations for HCV

 

Industry Tables
1. Pipeline Potential Thru 2018
2. Marketed Products’ Potential
3. Sector Selected Companies M&A Activities
4. Expected Drug Clinical Milestones

 

Browse more report on Pharmaceuticals


Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech” report OR for any other market research and intelligence needs you may have for your business.

Rescooped by mark igbinedion from Pharmaceuticals - Healthcare and Travel-tourism
Scoop.it!

Environmental Markets for Biotechnology

Environmental Markets for Biotechnology | Pharma-News | Scoop.it
Environmental Markets for Biotechnology This study provides a comprehensive and detailed analysis of the current and forecasted market from 2013 through 2018 for environmental biot - Market Research Reports and Industry Analysis...

Via sandhya kamath
more...
No comment yet.
Rescooped by mark igbinedion from Pharmaceutics_R&D
Scoop.it!

The changing face of corporate venturing in biotechnology

The changing face of corporate venturing in biotechnology | Pharma-News | Scoop.it
Corporate venture funds are playing an increasingly important role in supporting life science commercialization. 

Corporate venturing—the practice of establishing a unit of a corporation with the mandate to make strategic investments in entrepreneurial ventures—has emerged as one of the most prominent strategies for opening up innovation to external ideas and knowledge in the life sciences. Venture arms of pharmaceutical and large biotech companies leverage capital surplus generated through traditional revenue streams to create options for future product pipelines, enable access to innovative compounds and share the costs of risky early stage development with external partners. (...) - von Krogh G et al., Nature Biotechnology 30, 911–915 (2012)


Via Julien Hering, PhD
more...
No comment yet.
Rescooped by mark igbinedion from Technoculture
Scoop.it!

Honda's ASIMO robot is now surprisingly human

Honda's ASIMO robot is now surprisingly human | Pharma-News | Scoop.it

Honda has been working on the ASIMO humanoid robot for almost 30 years, and it shows.


Via Luca Baptista
more...
Manda Pahl's curator insight, April 17, 2014 12:38 AM

Its crazy how we have come with technology. For almost 30 years, Honda has been working on a humanoid robot and has been making remarkable progress. The robot moves much like a human would. In fact, in the video it seems like a human in a robot costume. This is a huge step in technology and this kind of advancements could help us in many aspects as life whether it be to help a disability or improve efficiency in industries.

Madison Blazing's comment, April 20, 2014 1:40 AM
This was extremely cool, and I find it amazing how far in technological advancements our society has come within recent years. This robot seemed way more lifelike than I was expecting it to be, and I definitely agree that this is a giant step that opens up numerous possibilities in the future.
Nick Sigrist's comment, May 2, 2014 8:55 PM
That's really neat to see, and the fact that it's taken 30 years is amazing. Our technology is advancing even quicker than we think it is, and faster than it shows just in our communities and cities. I think robots in general, humanoid or not, are a huge step for our tech industry and innovation in general.
Scooped by mark igbinedion
Scoop.it!

Pharma not so big on cloud for clinical trials - Government Health IT

Pharma not so big on cloud for clinical trials - Government Health IT | Pharma-News | Scoop.it
Pharma not so big on cloud for clinical trials
Government Health IT
Bringing a new drug to market is one of – if not the – most cost-intensive business activities in healthcare.
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Recruitment 2012: New job Contract Infrastructure Technical Specialist, Contract Cork – Ireland

New job Contract Infrastructure Technical Specialist, Contract Cork… http://t.co/SSUuX2Mb #hire #recruitment
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

The Art of Admission: Painting A Picture of Artistic Recruitment - The Choate News

The Art of Admission: Painting A Picture of Artistic RecruitmentThe Choate NewsWe all know that Choate's artists play an important role in our community.
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Tenn. to receive $1.1M in pharmaceutical agreement - Pharmaceutical Processing

Tenn. to receive $1.1M in pharmaceutical agreement - Pharmaceutical Processing | Pharma-News | Scoop.it
Boise WeeklyTenn. to receive $1.1M in pharmaceutical agreementPharmaceutical ProcessingTennessee Attorney General Bob Cooper says the state will receive $1.1 million for participating in a multistate agreement with drug maker Pfizer Inc.
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Leaders Of The Pharmaceutical Pack - Investing.com

Leaders Of The Pharmaceutical Pack
Investing.com
When it comes to the large cap pharma/biotech companies Allergan Inc (NYSE:AGN), and Merck & Company Inc (NYSE:MRK), may be the canaries in the coal mine.
more...
No comment yet.
Rescooped by mark igbinedion from Governance
Scoop.it!

New Policy on biotechnology

New Policy on biotechnology | Pharma-News | Scoop.it

Via Centre for Good Governance
more...
Centre for Good Governance's curator insight, February 11, 2014 4:11 AM

New Policy on biotechnology

Rescooped by mark igbinedion from Pharmaceutics_R&D
Scoop.it!

Novartis reboots brain division

Novartis reboots brain division | Pharma-News | Scoop.it
After years in the doldrums, research into neurological disorders is about to undergo a major change of direction.

In a sign that psychiatric-disease research is entering a new era, the pharmaceutical giant Novartis has hired an expert in neural circuitry, rather than pharmacology, to head its relaunched neuroscience division. (...) - by Alison Abbot, Nature, 08 October 2013


Via Julien Hering, PhD
more...
Magdalena Kawalec's curator insight, November 25, 2013 7:01 AM

Good decission. Befor to decide "how to design it" maybe better to know "how it works in the first place"

Rescooped by mark igbinedion from Market Research Report
Scoop.it!

Healthcare and Biotechnology Market in China 2023: Trends, Size and Growth Drivers Analyzed : ReportsnReports

Healthcare and Biotechnology Market in China 2023: Trends, Size and Growth Drivers Analyzed : ReportsnReports | Pharma-News | Scoop.it

Biotechnology and Healthcare Markets in China (9 Full Research Reports Collection)

 

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com  with (Biotechnology and Healthcare Markets in China) / report name in subject line and your contact details.

 

China's demand for biotechnology and healthcare markets has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This is a collection of 7 full market research reports on biotechnology, biotechnology equipment, biotechnology products, vaccines, cancer treatment, healthcare, drug delivery system, HIV, and biopharmaceuticals. These new studies examine China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.

 

Complete report of 1587 pages is available @ http://www.reportsnreports.com/reports/272523-biotechnology-and-healthcare-markets-in-china-9-full-research-reports-collection-.html.

 

Other New Reports by AMID: Common Disease Treatment Drugs Markets in China (13 Full Research Reports Collection) http://www.reportsnreports.com/reports/162548-common-disease-treatment-drugs-markets-in-china-13-full-research-reports-collection-.html.

 

Cancer Treatment Drugs Markets in China (12 Full Research Reports Collection) http://www.reportsnreports.com/reports/162547-cancer-treatment-drugs-markets-in-china-12-full-research-reports-collection-.html.

 

Medical Equipment and Supply Markets in China (10 Full Research Reports Collection) http://www.reportsnreports.com/reports/272524-medical-equipment-and-supply-markets-in-china-10-full-research-reports-collection-.html.

 

Browse more report on Biotechnology      

                                                          

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Biotechnology and Healthcare Markets in China (9 Full Research Reports Collection)” report OR for any other market research and intelligence needs you may have for your business.

 


Via Paul Nelson
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Six Tech Trends That Will Shape the Pharmaceutical Industry in 2013 | Emerging Technologies content from IndustryWeek | PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK

Six Tech Trends That Will Shape the Pharmaceutical Industry in 2013 | Emerging Technologies content from IndustryWeek | PHARMA MULTI-CHANNEL MARKETING  by PHARMAGEEK | Pharma-News | Scoop.it
Whether it’s utilizing data analytics to identify the best-targeted and most cost-effective therapy or using social media to engage with customers, new modes of technology will continue to play a role in life sciences organizations.
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Takeda and Ajinomoto receive approval for risedronate sodium hydrate formulation in Japan - Pharmaceutical Business Review

Takeda and Ajinomoto receive approval for risedronate sodium hydrate formulation in Japan - Pharmaceutical Business Review | Pharma-News | Scoop.it
Takeda and Ajinomoto Pharmaceuticals have received approval from Japan's Health, Labour and Welfare Ministry for their Actonel 75 mg tablets and Benet (#Pharma: Takeda and Ajinomoto receive approval for risedronate sodium hydrate formulation in Japan...
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Executive Search Dating's 'Holidating' Survival Guide For Vancouver Singles - SYS-CON Media (press release)

Executive Search Dating's 'Holidating' Survival Guide For Vancouver Singles - SYS-CON Media (press release) | Pharma-News | Scoop.it
Executive Search Dating's 'Holidating' Survival Guide For Vancouver SinglesSYS-CON Media (press release)"To date or not to date, that is the question," says Paddi Rice, President and Founder of Executive Search Dating.
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Bitter pill that comes with having large drugs sector - Irish Times

Bitter pill that comes with having large drugs sector - Irish Times | Pharma-News | Scoop.it
Irish TimesBitter pill that comes with having large drugs sectorIrish TimesThe nature of the lobbying of Taoiseach Enda Kenny by the pharmaceutical industry, as disclosed in this newspaper during the week, illustrates the power of the industry, and...
more...
No comment yet.
Scooped by mark igbinedion
Scoop.it!

Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012 | Dec 14 ... - SBWire (press release)

Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012 | Dec 14 ...SBWire (press release)Global Market Direct's pharmaceuticals report, “Daewoong Pharmaceutical Co., Ltd.
more...
No comment yet.